Filing Flows › Coherus Oncology (CHRS) › Q3 2026 › vs Q3 2025
Coherus Oncology (CHRS) Q3 2026 vs Q3 2025 (year over year)
Coherus Oncology's revenue rose $2.7M (+23%) from $11.6M in Q3 2025 to $14.3M in Q3 2026. The biggest changes: Toripalimab +$2.8M (+25%); Other revenue −$137K (-34%).
Coherus Oncology, Q3 2026: revenue $14.3M (+23% year over year), operating margin -235.7%, net loss $39.3M, operating cash flow −$34.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Toripalimab | $14.0M | $11.2M | $2.8M | +25% |
| Other revenue | $265K | $402K | −$137K | -34% |
| Revenue | $14.3M | $11.6M | $2.7M | +23% |
| Net loss | $39.3M | $35.5M | $3.8M | +11% |
| Costs & expenses | $53.6M | $56.1M | −$2.5M | -4% |
| Operating costs | $47.9M | $55.9M | −$8.0M | -14% |
| Interest & other, net | $5.2M | $184K | $5.0M | 28× |
| Income tax | $459K | −$9.0M | $9.4M | — |
| Cost of revenue | $4.1M | $3.7M | $371K | +10% |
| Research & development | $22.6M | $27.3M | −$4.6M | -17% |
| SG&A | $21.2M | $24.9M | −$3.7M | -15% |
| Operating cash sources | $39.3M | $35.5M | $3.8M | +11% |
| Depreciation & amortization | $853K | $300K | $553K | +184% |
| Share-based compensation | $3.7M | $3.4M | $293K | +9% |
| Working capital & other | $780K | −$14.5M | $15.3M | — |
| Cash used in operations | $34.0M | $46.3M | −$12.3M | -27% |
| Net loss absorbed | $39.3M | $35.5M | $3.8M | +11% |
Questions
How much did Coherus Oncology's revenue grow year over year in Q3 2026?
Coherus Oncology's revenue rose $2.7M (+23%) from $11.6M in Q3 2025 to $14.3M in Q3 2026.
What drove Coherus Oncology's revenue change in Q3 2026?
Toripalimab +$2.8M (+25%); Other revenue −$137K (-34%).